Viruses are small obligate intracellular parasites with either a RNA or DNA genome that are surrounded by a protective protein coat and transfer their genetic material to infected cells. Lentivirus ...

Thorough lentivirus characterization is essential for generating the highest quality gene therapy. Traditional methods only look at one piece of the puzzle, require purified samples, and can take days ...

Lentivirus is a genus in the family of Retroviridae that is very suitable for remodeling into gene transfer vectors due to its stable transgene expression, the ability to reach the nuclei of the ...

In spite of advances in conventional four-plasmid transient transfection methods and development of inducible stable production cell lines, production of replication-defective lentiviral vectors in ...

Lentiviruses have the unique ability amongst retroviruses of being able to infect non-cycling cells. Vectors derived from lentiviruses have provided a huge advancement in technology and seemingly ...

During the virtual Bioprocessing Summit in August, Cytiva reported that its new filtration process has advantages compared to traditional centrifuge approaches for removing viruses from suspension ...

Lentiviral transduction is a popular delivery platform for applications such as CAR-T cell engineering or CRISPR-Cas9 gene editing, as it can transduce both dividing and non-dividing cells and ...

Through a recent agreement with Oxford Genetics, Aldevron will now be providing the plasmids necessary for lentivirus production to their customers, according to an announcement made last week at the ...

BOSTON, MA, USA and BERLIN, Germany, May 17, 2023 / B3C newswire / -- ProBioGen today announced the launch of their lentivirus (LV) packaging cell line Lenti.RiGHT™ as a new platinum standard for LV ...

ProBioGen’s Lenti.RiGHT is a lentivirus production platform for use in gene transfer applications. ProBioGen, a Berlin-based company specializing in the development and manufacture of APIs, announced ...

LONDON, UK / ACCESSWIRE / November 15, 2023 / Hemogenyx Pharmaceuticals plc (LSE:HEMO), the biopharmaceutical group developing new therapies and treatments for blood diseases, is pleased to announce ...